FDA PMA FDA Class 3 Approved (Withdrawn) 🇺🇸 United States

Lithotripter, Shockwave (For Treating Gallbladder Stones)

PMA: P970042 · Decision Sep 5, 2000
Classifications
1
FEI Numbers
0
Registration Numbers
0

Basic Information

Device Name
Lithotripter, Shockwave (For Treating Gallbladder Stones)
Trade Name
MEDSTONE STS LITHOTRIPTER
PMA Number
P970042
Device Class
FDA Class 3
Product Code
NCV
Generic Name
Lithotripter, shockwave (for treating gallbladder stones)
Medical Specialty
Unknown
Advisory Committee
Gastroenterology, Urology
Decision
Approved (Withdrawn)
Decision Code
APWD
Decision Date
September 5, 2000
Date Received
September 4, 1997
Expedited Review
N
Docket Number
00M-1515

Advisory Committee Statement

APPROVAL FOR THE MEDSTONE STS(TM) LITHOTRIPTER IN CONJUNCTION WITH ACTGALL(R). WHEN USED WITH THE DRUG, THIS DEVICE IS INDICATED FOR THE TREATMENT OF SYMPTOMATIC, SOLITARY, RADIOLUCENT, NON-CALCIFIED GALLSTONES (BETWEEN 4 AND 20 MM IN MAXIMUM DIAMETER) IN ADULT PATIENTS FOR WHOM SURGICAL REMOVAL OF THE GALLBLADDER IS MEDICALLY CONTRAINDICATED AND IN SYMPTOMATIC HIGH-RISK PATIENTS WHO HAVE ACTIVELY REFUSED SURGERY. COMBINATION THERAPY CONSISTS OF 1) ADMINISTRATION OF ACTIGALL(R) (8-10 MG/KG/DAY) FOR AT LEAST TWO WEEKS PRE-LITHOTRIPSY, 2) LITHOTRIPSY TREATMENTS OF UP TO 2000 24 KV SHOCKS, AND 3) CONTINUED ADMINISTRATION OF ACTIGALL(R) UNTIL A STONE-FREE STATE IS ACHIEVED.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
NCV Lithotripter, Shockwave (For Treating Gallbladder Stones)